On January 6, 2023 lecanemab, which may moderately slow mild cognitive decline and reduce amyloid-β plaques in patients with early Alzheimer disease, gained accelerated approval from the US Food and Drug Administration (FDA).
About 2 in 10 people who receive lecanemab develop brain changes called amyloid-related imaging abnormalities (ARIA), which involves brain bleeding, brain swelling or a combination of the two.
On January 6, 2023 lecanemab, which may moderately slow mild cognitive decline and reduce amyloid-β plaques in patients with early Alzheimer disease, gained accelerated approval from the US Food and Drug Administration (FDA).
这个听起来很危险啊
当然是看医生给个评估啊。现在流行的是CDR-SB评分系统。9.5分以上才算中度痴呆。
国内也用这个评分系统吗?
请问ARIA是什么?
脑部amyloid 沉积可以做PET 检测出来,和尸检的结果基本差不多。就是amyloid 沉积和老年痴呆不是完全相关,现在还有很多地方没有搞清楚。
我觉得现在所有沿着这条线research的都是barking on the wrong tree
正解 这也是这个病找药的最大难点之一, 因为连怎么定义有效都没有个可靠量化的标准
脑部扫描奥兹海默是大脑萎缩还是小脑萎缩?